|
SOCIETY FOR INHERITED METABOLIC DISORDERS |
19 October, 2019 | Study Opportunity: Applied Therapeutics is currently enrolling a Phase 1/2 study of AT-007 in adults (age 18 and older) with galactosemia. The study, called ACTION-Galactosemia, will investigate safety and pharmacokinetics (PK) of AT-007, a central nervous system (CNS) penetrant Aldose Reductase Inhibitor in healthy volunteers, and will then explore safety, PK and biomarker effects in adult subjects with Galactosemia. If you are a patient or family member interested in receiving information about this trial, please email to galactosemia@appliedtherapeutics.com. For more information about the study, please visit: https://www.appliedtherapeutics.com/galactosemia, |